எம்மா ரோப்பர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from எம்மா ரோப்பர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In எம்மா ரோப்பர் Today - Breaking & Trending Today
Ipsen: ESMO 2021: Cabometyx Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(2) Regulatory News: Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib (CABOMETYX) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC) met one of the primary endpoints, demonstrating significant improvement in progression-free survival (PFS) at the planned primary analysis. A prespecified interim analysis for the second primary endpoint of overall survival (OS), conducted at the same time as the primary analysis for PFS, showed a trend favoring the combination of cabozantinib and atezolizumab, but did not reach statistical significance. Based on the preliminary OS data, Exelixis anticipates that the probability of reaching statistical significance at the time of the final analysis is low. The trial will continue as planned to the final analysis of OS; results are anticipated in early 20 ....
Ipsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results 1 Detailed results will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Participation in the collaboration will provide Ipsen with access to full trial data to support potential future regulatory submissions Disclaimer: Intended for international media and investor audiences only Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has exercised its option to collaborate with Exelixis, Inc. (Exelixis) in the pivotal COSMIC-311 Phase III trial. COSMIC-311 is evaluating Cabometyx (cabozantinib) 60 mg versus placebo in people living with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies. ....
Ipsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
More than £1 million raised for injured Patterdale mountain rescuer Chris Lewis Chris Lewis More than £1 million has been raised for the Patterdale mountain rescue volunteer critically injured following a 150-metre fall in February â but much more is still needed. Chris Lewis, 60, remains in hospital after sustaining life-altering injuries during a callout to a camper suffering from chest pains at Red Screes, near Kirkstone Pass, during lockdown. A fund set up by Lake District Search and Mountain Rescue Association on JustGiving to help pay for Chrisâ medical needs and his familyâs wellbeing, has now reached £1,029,009.86. The sum is made up of £856,939.12 which has been directly donated and an estimated £172,214.74 of Gift Aid, which can be claimed back from Her Majestyâs Revenue and Customs. ....